Potent and selective GLUK5
(GluR5)-subunit containing kainate receptor antagonist (apparent KD
= 402 nM); active enantiomer of UBP 296
(Cat. No. 2078). Displays ~ 260-fold selectivity over AMPA receptors, ~ 90-fold selectivity over recombinant human GLUK6
- and GLUK2
-containing kainate receptors and has little or no action at NMDA or group I mGlu receptors. Selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibers. Also protects against soman-induced seizures and neuronal degeneration for up to 30 days when administered one hour after soman exposure.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
Dolman et al.
Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist.
More et al.
The Limitations of Diazepam as a Treatment for Nerve Agent-Induced Seizures and Neuropathology in Rats: Comparison with UBP302.
Apland et al.
The citations listed below are publications that use Tocris products. Selected citations for UBP 302 include:
Showing Results 1 - 1 of 1